TABLE 1

Patient demographics and baseline characteristics by deprivation quintile for the Salford Lung Study (SLS) of COPD and SLS asthma (total study populations)

CharacteristicDeprivation quintile#
12345
SLS COPD
 Patients1453/2791601/2791391/2791209/2791137/2791
 Age years65.0±9.867.2±10.168.8±9.570.4±8.470.1±9.5
 Males733 (50)305 (51)197 (50)111 (53)78 (57)
 BMI kg·m−228.0±7.127.9±6.127.6±5.427.6±5.427.1±5.0
 Current smokers763 (53)247 (41)156 (40)70 (33)48 (35)
 Duration of COPD ≥5 years764 (53)305 (51)204 (52)127 (61)75 (55)
 COPD exacerbations in the year prior to randomisation2.1±2.11.9±1.82.0±1.82.0±1.91.5±1.4
SLS asthma
 Patients855/4218834/4218856/4218831/4218842/4218
 Age years47.1±15.847.9±16.049.9±16.250.0±16.954.1±16.0
 Males346 (40)330 (40)359 (42)344 (41)353 (42)
 BMI kg·m−231.0±7.630.6±7.130.4±7.129.1±6.228.5±5.8
 Current smokers276 (33)218 (26)179 (21)108 (13)65 (8)
 Duration of asthma ≥10 years627 (73)624 (75)634 (74)611 (74)638 (76)
 Severe asthma exacerbations in the year prior to randomisation0.7±1.20.7±1.20.7±1.30.6±1.00.5±0.9
 Uncontrolled asthma+462 (54)384 (46)354 (41)282 (34)231 (27)
 Daytime symptoms more than twice a week§772 (90)760 (91)781 (91)750 (90)755 (90)
 SABA use more than twice a week§689 (81)648 (78)640 (75)552 (66)504 (60)
 Activity limitations in the past week§501 (59)474 (57)454 (53)374 (45)351 (42)
 Nocturnal symptoms/awakenings in the past week§504 (59)446 (53)409 (48)383 (46)365 (43)

Data are presented as n/N, mean±sd or n (%). BMI: body mass index; SABA: short-acting β2-agonist. #: where 1 is the most deprived and 5 is the least deprived; : based on patients with available data; +: Asthma Control Test score ≤15; §: based on patients' recall of asthma symptoms in the past week, as assessed at the baseline (randomisation) visit.